CD4 and tuberculosis: This study found that retroviral-infected patients receiving HAART treatment were at increased risk for severe hepatotoxicity if they were co-infected with hepatitis B virus or hepatitis C virus, co-infected with tuberculosis or had a CD4+T-cell count below 200 cells/mm3.